Adjuvant therapy in adrenocortical carcinoma: prognostic factors and treatment options

Ruaa Al-Ward1,2, Celeste Zsembery3 and Mouhammed Amir Habra1

1Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
2Department of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, Texas, USA
3Departments of Medicine and Pediatrics, Baylor College of Medicine, Houston, Texas, USA

Correspondence should be addressed to M A Habra: mahabra@mdanderson.org

Abstract

Adrenocortical carcinoma (ACC) is a rare cancer with high recurrence rates and heterogeneous clinical behavior. The role of adjuvant therapy remains unclear because of the challenges in collecting high-quality data for a rare cancer. The current treatment recommendations and guidelines for adjuvant therapy are mostly derived retrospectively from national databases and the treatment outcomes of patients seen in referral centers. To better select patients for adjuvant therapy, multiple factors need to be considered including staging, markers of cellular proliferation (such as Ki67%), resection margins, hormonal function, and possibly genetic alterations of the tumor as well as patient-related factors such as age and performance status. Adjuvant mitotane remains the most commonly used adjuvant therapy in ACC based on clinical practice guidelines, though emerging data from ADIUVO trial (mitotane vs observation in low-risk ACC) suggest that mitotane use in low-risk patients may not be needed. An ongoing clinical trial (ADIUVO-2) is evaluating the role of mitotane vs mitotane combined with chemotherapy in high-risk ACC. The use of adjuvant therapy has been controversial but can be justified in select patients with positive resection margins or after the resection of localized recurrence. A prospective study is needed to study the role of adjuvant radiation in ACC as radiation is expected to help only with local control without impact on distant microscopic metastases. There are no recommendations or published data about using adjuvant immunotherapy in ACC, but this may be a future study after establishing the efficacy and safety profile of immunotherapy in metastatic ACC.

Introduction

Adrenocortical carcinoma (ACC) is a rare aggressive malignant tumor with a poor prognosis despite its well-known heterogeneous behavior. It was first described in a case series by Ramsay (1899). Despite the improvements in diagnostic imaging and the recognition of ACC over the last century, its annual incidence in adult patients has remained relatively stable which is estimated to be around 0.7–2 cases per million people (Kerkhofs et al. 2013).

ACC has a bimodal age distribution with a small peak before the age of 5 years, primarily for TP53 gene mutations (~50–80% of pediatric cases) and a larger peak in patients 40–60 years old (Else et al. 2014a). Most ACC cases are sporadic, with a few linked to genetic syndromes such as Li-Fraumeni syndrome, Lynch syndrome, Carney complex, and multiple endocrine neoplasia type 1 syndrome. ACC is recognized more commonly in...
female patients (1.5–2.5:1) compared to male patients (Jasim & Habra 2019).

Over the past few decades, improvements in surgical techniques and postoperative care for patients with ACC have made surgery the crucial initial step in ACC management (Grubbs et al. 2010). However, despite surgeons’ best efforts, ACC has a recurrence rate as high as 30–70% (Ayala-Ramirez et al. 2013, Glenn et al. 2019, Turco et al. 2021) and is associated with substantial decreases in life expectancy and a poor 5-year overall survival (OS) rate ranging between 0% and 45% (Margonis et al. 2016a, Tran et al. 2016). Thus, effective adjuvant therapy is critically needed to improve the prognosis in adult patients with ACC.

Adjuvant therapy, including chemotherapy, immunotherapy, hormonal therapy, and radiotherapy, has been widely used in many cancers such as prostate cancer and breast carcinoma among others (Bolla et al. 2012, Masuda et al. 2017).

Over the past few decades, multiple reports were published about the optimal post-surgical therapies to decrease ACC recurrences but only two clinical trials (ADIUVO and ADIUVO-2 trials) have been launched to prospectively validate the published retrospective data (Terzolo et al. 2021) (ClinicalTrials.gov identifier: NCT03583710). These therapies include mitotane, the first antineoplastic drug used for patients with advanced ACC; radiation therapy (RT); chemotherapy, etoposide, doxorubicin, cisplatin, streptozocin, and gemcitabine widely used in retrospective studies; and, more recently, immunotherapy and targeted molecular therapy.

In this review, we summarized the published experience regarding adjuvant therapy in ACC and prognostic factors. In addition, we provided detailed descriptions of the use of RT, mitotane, and cytotoxic chemotherapy in these patients based on the current status of literature. We also discussed the potential use of immunotherapy in ACC and provided recommendations regarding the choice of therapy based on the risk factors associated with ACC prognosis.

**Prognostic factors in localized ACC**

Surgical resection by an expert surgeon is the most important first step in the management of ACC. While it is hard to assess the level of surgical expertise, it is highly recommended to refer those patients to centers known for their experience in ACC management to ensure the highest level of possible care.

After resection, given the rarity of ACC and the absence of prospective studies, multiple prognostic factors can be used to predict the risk of disease recurrence and justify the use of adjuvant therapy. These factors include the patient’s disease stage, surgical margins, cell proliferation markers, hormonal status, age, genetic profile, and the surgical approach used.

**Stage**

ACC staging is an independent predictor of disease recurrence. In a 2009 study from the German ACC registry including 416 ACC patients, the 5-year disease-specific survival rate was 82% for patients with stage I, 58% for stage II, 55% for stage III, and 18% for stage IV ACC patients (Fassnacht et al. 2009). Additionally, a 2013 study of 330 patients at the University of Texas MD Anderson Cancer Center showed that disease-specific survival depends on the disease stage. Patients’ median overall survival (OS) duration was 24.1 years for stage I, 6.1 years for stage II, 3.5 years for stage III, and 0.9 years for stage IV ACC (Ayala-Ramirez et al. 2013).

Using tumor size, extension, regional lymph node involvement, and the evaluation of distant metastasis (tumor, node, metastasis (TNM) classification) are the key elements in ACC staging (Jasim & Habra 2019). The TNM classification of ACC was first proposed in 2004 by the International Union Against Cancer and the American Joint Committee on Cancer. Later, the 2008 European Network for the Study of Adrenal Tumors (ENSAT) staging system reclassified stage III tumors as all locally advanced tumors and stage IV tumors as only those with distant metastases at the time of the initial diagnosis (Fassnacht et al. 2009). This staging system considering stage IV only in patients with distant metastases was also recently adopted by the American Joint Committee on Cancer Eighth edition (Amin et al. 2017).

**Surgical margins**

Positive surgical margins are associated with high recurrence rates in many cancers, including common malignancies such as prostate and breast cancers (Heiss et al. 2017, Zhang et al. 2018). Positive surgical margins (R1 resection) are a risk factor for worse outcomes in ACC and are associated with shorter OS and recurrence-free survival (RFS) compared to patients with negative margins (R0 resection) (Ayala-Ramirez et al. 2013, Nowak et al. 2018). Data from the National Cancer Database from 1985 to 2005 showed that the rate of margin-positive resection
is high, around 19% (Bilimoria et al. 2008). Additionally, a German study suggested that the OS of patients with positive margins (R1) stage II disease is similar to or worse than that of patients with completely resected (R0) stage III disease (Fassnacht et al. 2009).

From 13 tertiary academic centers in the United States, the 5-year RFS rate in univariate analysis was higher among patients with R0 resection than among patients with R1 resection (30.3% vs 13.8%, respectively; HR, 1.71; 95% CI, 1.05–2.78; P=.03) (Margonis et al. 2016b). Another study of 330 patients from a single center confirmed this finding (Ayala-Ramirez et al. 2013). However, in both studies, this finding becomes statistically insignificant in the multivariate analysis and neither study could confirm surgical margins as independent predictors of RFS. This is likely because both studies were underpowered to detect the effect of margin status on RFS.

In 2018, a National Cancer Database meta-analysis of 1553 patients with ACC found that those with negative margins (R0) had a significantly longer median survival duration (57.6 months; 95% CI, 48.5–66.0) than those with positive margins both microscopically (22.4 months; 95% CI, 17.6–33.5) with hazards ratio (HR) of 1.76 (95% CI, 1.37–2.26; P < 0.001) and macroscopically (13.7 months; 95% CI, 5.8–26.8) with HR of 2.10 (95% CI, 1.21–3.65; P = 0.009) (Anderson et al. 2018).

Current guidelines do not have specific recommendations for adjuvant therapy in patients with stage I-II ACC with R0 resection and Ki67 percentage scores less than or equal to 10%, but they highly recommend adjuvant therapy for patients with positive surgical margins (Fassnacht et al. 2018).

**Cell proliferation markers**

Ki67 proliferation index is among the most powerful prognostic molecular marker in ACC. The largest study, from 2015, looked at 319 German patients and 240 patients from 3 other European countries showed that the HR of the RFS increased sequentially with the Ki67 index, with 10% and 20% percentage scores correlating to HRs of 1.94 (P = 0.0034) and 2.58 (P = 0.001), respectively (Beuschlein et al. 2015). The median OS also correlated with the Ki67 index. Ki67 percentage scores of less than 10%, of 10–19%, and ≥20% or greater were associated with median OSs of 180.5 months, 113.5 months, and 42 months, respectively. Ki67 has also been validated in the pediatric ACC population, where it reliably predicts worse outcomes (Martins-Filho et al. 2021, Riedmeier et al. 2021). A study that included 146 adult patients and 44 pediatric patients with ACC showed that an increase of even 1% in the Ki67 index could have a significant impact on OS and disease-free survival (DFS) (P < .001) (Martins-Filho et al. 2021).

The mitotic rate of the tumor cells has been also associated with poor outcomes. A 2010 study by the University of Michigan found significantly worse outcomes (time to recurrence, P = 0.011; time to death, P = .004) in patients whose tumor cells had a high (20 mitoses per 50 high-power fields) rate of mitosis compared with a low (12 mitoses per 50 high-power fields) rate of mitosis (Miller et al. 2010). However, Ki67 index was found to be superior to mitotic index in predicting OS (Duregon et al. 2014). Currently, the ENSAT guidelines recommend all patients should have pathological staging using the Weiss system, which includes mitotic rates as part of its criteria (Fassnacht et al. 2018). Thus, the Ki67 index and Weiss scores are important components in pathological disease staging.

**Hormonal status**

Hormonally functional ACCs have been reported in 50–75% of cases (Else et al. 2014b), and multiple studies have shown that hormonally functional status is a predictor of poor prognosis. A meta-analysis of 19 studies, including a cohort study of 3814 patients with different stages of ACC, found that the mortality relative risk was 1.54 in hormonally functional tumors compared with hormonally nonfunctional tumors in data from models adjusting for tumor stage (95% CI, 1.28–1.85) and 1.71 in cortisol-secreting tumors compared with non-cortisol-secreting tumors (95% CI, 1.18–2.47) (Vanbrabant et al. 2018). Additionally, a recent study of 62 patients with ACC done by the National Cancer Institute and Memorial Sloan Kettering Cancer Center found that 78% of the 18 patients who had OS less than 12 months had hormonally functional tumors, whereas only 48% of those who survived more than 24 months had hormonally functioning tumors (Ayabe et al. 2020).

Of all the types of hormonally active tumors, glucocorticoid tumors have the poorest prognosis, which is likely due to their immunosuppressive nature and considerable systemic impacts. In a recent study of 164 tumor samples from patients with ACC, it was found that the presence of a high number of tumor-infiltrating T cells (TILs), including T helper, cytotoxic T, and regulatory T cells, was associated with better survival (HR for death, 0.47; 95% CI, 0.25–0.87), but the presence of TILs was negatively impacted by excess glucocorticoids (phi = −0.290; P = 0.009) (Landwehr et al. 2020). The study concluded that patients with excess glucocorticoids and...
low numbers of TILs had a particularly poor median OS of 27 months, whereas those with sufficient numbers of TILs and no excess glucocorticoids had a median OS of 121 months (Landwehr et al. 2020).

**Age**

ACC can affect any age group, although it most typically affects patients in their 50s to 60s and patients younger than 5 years old if they have a genetic predisposition. Age is an independent prognostic factor; older adults usually have a poorer prognosis. This is likely multifactorial related to increase in comorbidities and reduced tolerance to systemic therapy. It is unknown if age by itself is associated with a more aggressive tumor. A 2014 study of 391 ACC patients showed that age at the time of diagnosis was inversely related to OS (HR, 1.01; P=0.018) (Else et al. 2014b). Another study of 330 patients with ACC in a tertiary care center found that increased age at the time of the diagnosis had an HR of 1.003 (95% CI, 1.003–1.024; P = .0089) (Ayala-Ramirez et al. 2013). Similarly, a cohort study of 66 patients found that having an age older than 50 was an independent variable associated with decreased OS (HR, 1.09; P = .001) (Nowak et al. 2018). The 5-year survival rate for patients less than 50 years old was 66.9% (95% CI, 44.2–82.1), which is much better than patients older than 50 years 29.3% (95% CI, 14.1–46.3) (P = 0.004).

**Genetic profile**

Although most ACCs develop sporadically, a minority of cases are seen in the context of familial cancer syndromes, including Li-Fraumeni syndrome, Beckwith-Wiedemann syndrome, Carney complex, and multiple endocrine neoplasia type 1 (Angelousi et al. 2016). As ACC can be the initial presentation of these familial syndromes, it is important to consider further genetic workup.

In 2016, The Cancer Genome Atlas pioneered the first comprehensive, integrated genomic characterization study of 91 patients who were from six different countries and who had histologically confirmed ACC group.

This study analyzed ACC’s clinical and pathologic features, genomic alterations, DNA methylation profiles, and RNA and proteomic signatures, providing a worldwide perspective into the critical alterations responsible for ACC tumorigenesis and progression. The most frequent genetic alterations discovered were P53, ZNRF3, CDKN2A, CTNNB1, TERT, and PRKAR1A. Consensus clustering analyses were created based on alteration in DNA copy number, DNA methylation, mRNA expression, and micro RNA expression, which resulted in three molecular classification subtypes with different outcomes (Zheng et al. 2016). The disease progression rates were 7%, 56%, and 96% for the cluster of cluster subtypes I, II, and III, respectively. In addition, the cluster of cluster subsets II and III were found more frequently in stage III/IV tumors (47% and 52%, respectively) than were a cluster of cluster subset I (25%) (Zheng et al. 2016). Additionally, disease aggressiveness was identified by the whole-genome doubling.

In 2019, a prognostic study of 368 patients who underwent surgical removal of localized ACC found that molecular classification was an independent prognostic factor for OS and DFS (Assié et al. 2019). In this study, three discrete molecular classes – A1, A2, and A3 to B – were created based on the ENSAT guidelines and The Cancer Genome Atlas molecular classes of ACC. The 5-year OS rate was 9% for the A1 group, 45% for the A2 group, and 82% for the A3 to B group (P < 0.001). The HR for disease-related survival was 55.91 for group A1 compared with group A3 to B 95% CI, 8.55–365.40; P < 0.001).

Specific microarray gene markers, such as the differential gene expression of BUB1B/PINK1, improve the diagnosis and the prognostic assessment of ACC. ACC is predicted to have a poor prognosis and fatal outcome if the molecular predictor (DLGAP5–PINK1) is ≤3.22 (Fragoso et al. 2012). Similarly, G0S2 hypermethylation and silencing causing upregulation of cell cycle is the hallmark of rapidly recurrent or fatal ACC as it independently predicts shorter DFS and OS (Mohan et al. 2019).

Another analysis showed that overexpression of VAV2, which is a steroidogenic factor-1 dosage-dependent target, was an independent prognostic factor for shorter PFS and OS in a multivariate analysis (Sbiera et al. 2017). Furthermore, Ki67 and VAV2 expression were significantly correlated and could be used to stratify patients into high-risk and low-risk groups. These studies suggest that a patient’s genetic profile has a significant impact on prognosis and should be used in conjunction with other predictors. So far, there is no published data that correlates adjuvant therapy outcomes with underlying genetic alterations. Future studies can include an exploratory objective to study the correlation between select molecular factors and responses to adjuvant therapy.

**Surgical approach**

For many cancers, laparoscopic approaches are often favored, compared to open surgeries, because they are associated with shorter operative time, less blood loss,
and shorter hospital stays. However, in ACC, laparoscopic resection has been linked to inferior outcomes and high rates of positive resection margins. A study of 256 patients with ACC showed that, among patients who underwent laparoscopic rather than open surgery, there was a higher rate of positive resection margins (R1 or R2) (28.3% vs 17.6%; \(P=0.01\)) and a shorter median OS (10.9 months vs 19.6 months; \(P=0.005\)) (Cooper et al. 2013). Similarly, a Chinese study of 42 patients showed that the mean DFS for patients who underwent open vs laparoscopic adrenalectomy was 44.8 ± 35 months and 17.5 ± 10.4 months, respectively (\(P=0.023\)) (Zheng et al. 2018). The presumed reasons for the high rates of treatment failure after laparoscopic surgery are the higher rates of positive margin resections and the seeding of the laparoscopic tract with tumor cells, although this is debated in the literature. There are no randomized, controlled studies evaluating laparoscopic vs open adrenalectomies.

Meta-analyses of the literature have shown controversial outcomes when the laparoscopic and open surgical approaches were compared. Agourakis et al.’s meta-analysis of 4 studies with a total of 253 patients showed favorable 5-year survival in patients who underwent open vs laparoscopic adrenalectomy (\(P = 0.4\)) (Sgourakis et al. 2015), but 3 other meta-analyses showed no statistically significant differences between the 2 approaches in terms of recurrence rate and mortality. These studies include Mpaili et al.’s meta-analysis of 13 studies of 1171 patients, Autorino et al.’s analysis of 9 studies of 797 patients, and Langenhuijsen et al.’s analysis of 26 publications (Autorino et al. 2016, Langenhuijsen et al. 2016, Mpaili et al. 2018). However, all of these studies were observational, and some of them have partially reported oncological outcomes.

Therefore, open surgery remains the standard goal in ACC surgeries, especially for suspected ACC >6 cm. Laparoscopic resection can be considered on a case-by-case basis when an experienced surgeon is available and presuming the adrenal mass is <6 cm without any signs of local invasion or lymphadenopathy (Fassnacht et al. 2018, Liang et al. 2020).

Prognostic calculators

Several calculators were created to provide guidance for the best postoperative treatment course. However, neither has been the optimal tool for prognostication established yet or has been validated prospectively. Helsinki score was created in 2015 to provide a prognostic indicator based on the combination of the morphology (mitoses and necrosis) and immunohistochemical (Ki-67) parameters (Pennanen et al. 2015). This score consists of a 3× mitotic rate (>5/50 high-power fields) ÷ 5 × presence of necrosis + proliferation index in the most proliferative area of the tumor. Patients with a score of 0–8.5 had OS of 100% at 2 years, while patients with a score of 8.5–17 (>17) had OS of 70% and 20%, respectively (\(P = 0.010\)) (Pennanen et al. 2015).

Another prognostic score was suggested in the same year using a composite score of (Ki67 index, tumor size, and presence of tumor venous thrombus) (Beuschlein et al. 2015). This score was able to discriminate the German ACC cohort registry of 319 patients into groups with different clinical outcomes and can be used to predict outcomes but not select adjuvant therapy.

Most recently, modified S-GRAS (stage, grade, resection status, age, symptoms) was validated in a large, multicenter retrospective study of 942 ACC patients (Elhassan et al. 2021). The updated score generated four S-GRAS groups 0–1, 2–3, 4–5, and 6–9 depending on five factors which include modified ENSAT stages I–III (1–2 = 0; 3 = 1; 4 = 2), grade (Ki67 index 0–9% = 0; 10–19% = 1; ≥20% = 2 points), resection status (R0 = 0; RX = 1; R1 = 2; R2 = 3), age (<50 years = 0; ≥50 years = 1), and symptoms (no = 0; yes = 1). The higher the S-GRAS scores, the higher risk of disease progression. Comparing S-GRAS 0–1, patients with S-GRAS 2–3, 4–5, and 6–9 had, respectively, 2.8, 6.4, and 11.5 times (\(P < 0.0001\)) higher risk of disease progression. This system showed better performance compared to the ENSAT staging and Ki 67%.

Types of adjuvant therapy in adrenocortical carcinoma

Radiation therapy

In 1896, Wilhelm Roentgen discovered the X-ray. Three months later, the X-ray was used for the diagnosis of different diseases, and 3 years later, RT was used for skin cancer treatment. In 1932, the ionizing radiation chamber was introduced, helping physicians with radiation dose measurements (Thoraeus 1932). Over the subsequent 90 years, phenomenal leaps forward in technology have honed RT to very delicate, precise treatments for a variety of solid tumors.

Adjuvant RT is widely used in different malignancies to prevent tumor recurrence. For example, it is commonly used as an adjuvant treatment for common malignancies such as breast cancer and prostate cancer. In breast cancer patients, it is estimated that the number needed to treat with adjuvant RT is 6.3 patients to add 1 survivor at 10 years (Early Breast Cancer Trialists’ Collaborative Group 2011). Similarly, the use of adjuvant RT for prostate cancer
significantly improved the 10-year, metastasis-free survival with a median of 14.7 years (HR, 0.75; 95% CI, 0.55–1.02; P=0.16) (Thompson et al. 2006). Despite the favorable outcome of using adjuvant RT in many types of cancer, data regarding the efficacy of using adjuvant RT in ACC is conflicting; thus, RT is used less often to treat patients with ACC.

The first published retrospective study regarding the efficacy of adjuvant RT in patients with ACC was conducted in 2006. The study included 28 patients: 14 controls (surgery only) and 14 in the adjuvant treatment group. The 5-year probability of being free of local recurrence was 79% in the adjuvant RT group compared with 12% in the surgery-only group (P=0.01); however, OS did not differ much between the groups (Fassnacht et al. 2006). Later, a 2018 study of 1184 ACC patients in the National Cancer Database found that only 171 had received adjuvant RT (Nelson et al. 2018). Of those patients, adjuvant RT was associated with a 40% decreased risk of death (HR, 0.60; 95% CI, 0.40–0.92; P=0.02) in patients with positive surgical margins. Unfortunately, there was no clear benefit in older patients with a nodal-positive disease or high-grade histology. A recent meta-analysis of 6 studies with a total of 238 participants compared patients who received adjuvant RT with those who received surgery alone and found that adjuvant RT was associated with significantly higher OS (odds ratio, 2.27; 95% CI, 1.23–4.18; P=0.009). The etiologies related to the observed association between adjuvant RT and improved survival in a subset of ACC patients with positive margins remain unclear. Until we have future prospective studies to confirm if this association is true, we speculate that in some patients who will only develop local recurrence, RT may play a role in improving outcomes, while RT may have limited role in patients who develop distant and local recurrences.

On the other hand, another study using the National Cancer Database registry of 1557 patients with ACC compared adjuvant RT vs surgery alone in patients with a higher risk of recurrence using a propensity-matched analysis found worse median survival in patients receiving RT compared to those who underwent surgery alone (19.5 vs 22.8 months; P=0.042). Of note, patients who received RT in this study were more likely to have begun with incomplete resection and evidence of lymphovascular invasion. The authors concluded that RT does not confer a survival benefit when used as an adjuvant and recommended an individualized approach for adjuvant RT for ACC patients with high-risk features (Chen et al. 2021). Thus, further prospective studies are needed to fully understand the benefit of adjuvant RT in ACC.

Mitotane

Mitotane, the only antineoplastic drug used in the treatment of ACC, is a derivative compound of the insecticide dichloro-diphenyl-trichloroethane (DDT). Mitotane was first isolated from DDT in the 1940s. Its efficacy in treating ACC was first reported in 1959 in a case study (Bergenstal 1959). It was then introduced to the market in the 1960s (Corso et al. 2021). Although it has been more than 50 years since the introduction of mitotane in the clinic, its precise mechanism of action is still not fully known. Several mechanisms have been proposed (Fig. 1). These include (1) altering mitochondrial enzymes by covalently binding to cytochrome P450 enzymes (CYP11A1, CYP11B1, CYP17A1, and CYP21A2), which are involved in steroidogenesis causing altered hormonal concentrations; (2) reducing the expression of key proteins in steroidogenesis, such as STAR protein and sterol-O-acyl-transferase 1 (SOAT1), on the transcriptional level which was recently correlated with aggressive behavior (Sbiera et al. 2015, Lacombe et al. 2020); (3) inhibiting SOAT1, leading to the accumulation of free cholesterol and thus causing cell death (Lin et al. 2012); (4) interfering with the mitochondrial respiratory chain function complexes I (ubiquinone oxidoreductase) and IV (cytochrome c oxidase), leading to the induction of mitochondrial membrane fragmentation; (5) initiating the apoptotic process by activating caspase 3 and caspase 7 (Corso et al. 2021); and (6) strongly inducing CYP3A4 activity, leading to glucocorticoid inactivation and increased steroid clearance (Chortis et al. 2013). Recently, SOAT1 was studied retrospectively in ACC patients treated with adjuvant mitotane but there was no correlation between SOAT1 expression and key clinical endpoints such as RFS (Weigand et al. 2020). In a prospective phase I study, using a selective SOAT1 inhibitor (nevanimibe) in patients with metastatic ACC did not yield meaningful responses possibly because of the limitation in achieving therapeutic drug levels to affect ACC cell survival.

Although mitotane is approved for use in metastatic ACC, its use as adjuvant therapy is still based on expert opinion, retrospective data, and clinical practice guidelines, given the lack of prospective evidence for its efficacy. According to the 2018 ENSAT guidelines, its use is recommended in ACC patients with high-risk features (Fassnacht et al. 2018), and many expert cancer centers recommend its use in the adjuvant setting (Puglisi et al. 2020). Mitotane onset of action is often delayed, and it takes about 3 months for its blood concentration to reach the therapeutic target for metastatic ACC (14–20 mg/L) (Terzolo et al. 2013). For adjuvant therapy, the therapeutic
target is still uncertain as the duration of treatment is needed to prevent disease recurrence (Puglisi et al. 2019).

Early, small studies on adjuvant mitotane, including a retrospective 1936–1987 study of 21 patients and a 2001 study of 11 patients, showed no significant benefit to patients (Bodie et al. 1989, Baudin et al. 2001). In contrast, a 1995 study of 26 patients and a 1998 study of 4 patients showed benefits (Kasperlik-Zaluska et al. 1995, Dickstein et al. 1998). It is difficult to interpret these studies as they lacked significant power, some involved multiple adjuvant therapies, different mitotane formulations, different doses, and few had matched control groups.

Larger, more recent studies have been supportive of adjuvant mitotane. A 2007 retrospective study of 177 patients in 8 Italian and 47 German centers used mitotane as adjuvant therapy after radical surgical resection performed between 1985 and 2005 and included a 10-year follow-up period (Terzolo et al. 2007). The median RFS was significantly longer in the mitotane group than in the Italian control group (42 months vs 10 months; HR, 3.79; 95% CI, 2.27–6.32; P < 0.001) and in the German control group (42 months vs 25 months; HR, 2.93; 95% CI, 1.74–4.940; P = 0.005) (Terzolo et al. 2007). This study was the first to challenge the belief that mitotane was ineffective and prove that small mitotane doses (1–5 g/day) have a favorable effect (Terzolo et al. 2007, Grubbs et al. 2010).

In 2010, an MD Anderson Cancer Center retrospective study of 218 patients showed that the median DFS for those patients treated with mitotane was 30 months vs 12 months in patients without mitotane (P = 0.05) (Grubbs et al. 2010). Another study of 30 patients treated with adjuvant mitotane showed improvement in DFS in patients with complete resection (HR for recurrence, 0.58; 95% CI, 0.29–1.15; P = 0.12) (Fassnacht et al. 2010). A 2019 study of 152 patients (100 patients with and 52 without mitotane treatment) stratified the patients by disease stage (I–II vs III), hormone secretion levels, and Ki-67 percentage scores showed that the nontreated group had a higher risk of recurrence than the mitotane-treated group (HR, 2.79; 95% CI, 1.58–4.91; P < 0.001) (Calabrese et al. 2019). Two other meta-analyses also showed that adjuvant mitotane was associated with prolonged OS (first study: HR, 0.69; 95% CI, 0.55–0.88; P < 0.01 and second study: HR, 0.7; 95% CI, 0.5–0.9) and RFS (first study: HR, 0.62; 95% CI, 0.42–0.94; P = 0.02 and second study: HR, 0.7; 95% CI, 0.5–0.9) (Fassnacht et al. 2018, Tang et al. 2018).
ADIUVO study was the first trial to use mitotane in a randomized, controlled setting but mostly designed to evaluate patients deemed at low risk for recurrence. Patient criteria for inclusion included having stage I–III ACC, R0 surgery, and a Ki67 percentage score of 10% or less. A total of 91 patients were enrolled in the study (45 patients treated with adjuvant mitotane and 46 in the observational arm). RFS and OS did not differ significantly between the two groups, although, in the observational arm, the HR for recurrence was 1.321 (95% CI, 0.55–3.32; P = 0.54) and the HR for death was 2.171 (95% CI, 0.52–12.12; P = 0.29) (Terzolo et al. 2021).

A second prospective, randomized trial of adjuvant therapy, the ADIUVO-2 trial, was launched in August 2018 for patients who are deemed to be at high risk for recurrence. In this trial, the efficacy of mitotane vs mitotane plus cisplatin and etoposide in terms of DFS and OS is being studied as adjuvant therapies for preventing ACC recurrence (ClinicalTrials.gov identifier: NCT03583710).

Cytotoxic chemotherapy

Given the aggressive nature of ACC, over half of patients undergo relapse after complete surgical resection. Currently, mitotane is the most commonly used adjuvant therapy drug, and data supporting the use of cytotoxic chemotherapy are limited. As such, the European Society of Endocrinology and European Society for Medical Oncology guidelines do not recommend standard adjuvant chemotherapy for patients with ACC but instead recommend case-by-case consideration based on the data available for systemic chemotherapy regimens (Fig. 2). Appropriate candidates for adjuvant chemotherapy are patients with a higher risk of relapse (i.e., those with one or more European Society of Endocrinology/European Society for Medical Oncology risk factors, including a Ki67 percentage score greater than 30%, a large tumor thrombus in the vena cava, stage IV disease, or R1 resection) (Fassnacht et al. 2020), as survival benefits have been demonstrated only for patients with locally advanced cancers (Al Asadi et al. 2021).

Although other solid malignancies have responded favorably to cytotoxic therapy, evidence for ACC remains limited for both adjuvant and palliative therapies. The FIRM-ACT trial of 2004–2010, which included 304 patients, was the first phase III randomized trial of chemotherapy in advanced or metastatic ACC, demonstrating that the platinum-based therapy (a combination of etoposide, doxorubicin, and cisplatin with mitotane) was superior to streptozocin plus mitotane (Fassnacht et al. 2020).

Recently, a retrospective multicenter cohort study of ACC in high-risk adults (n = 299) demonstrated that patients who received adjuvant, platinum-based chemotherapy (cisplatin or carboplatin plus etoposide) had a 65% reduction in recurrence, improved OS, and longer PFS.

Figure 2

Suggested algorithm for the management of localized adrenocortical carcinoma. ACC, adrenocortical carcinoma; ACTH, adrenocorticotropic hormone; DST, dexamethasone suppression test; R0, no evidence of tumor; R1, microscopic evidence of tumor; R2, macroscopic residual disease; RX, margins unknown.
(20.5 months vs 9.1 months; \( P < 0.00 \)) compared with patients without adjuvant chemotherapy (Kimpel et al. 2021).

Considering the lack of prospective evidence for adjuvant chemotherapy in high-risk ACC, the ADIUVO2 trial (ClinicalTrials.gov identifier, NCT03583710) was established. In this phase III, randomized, pragmatic, clinical trial, there will be a comparison of outcomes between patients receiving 2 years of adjuvant mitotane alone vs patients receiving 2 years of mitotane in addition to 3 months of cisplatin and etoposide. This study aims to enroll 240 patients (120 patients in each arm) who have undergone primary surgical resection for localized ACC and have a high risk of recurrence (stage I–III disease and a Ki67 percentage score \( \geq 10\% \)). The primary objective is RFS, and the secondary objectives include OS, clinical outcomes, adverse events, and quality of life.

**Immunotherapy**

Currently, research to determine immunotherapy targets for ACC is ongoing. It has focused primarily on salvage therapy for ACC tumors that have failed other treatments; to date, no study of immunotherapy as an adjuvant therapy has been performed (De Filpo et al. 2021). Monoclonal antibodies that successfully target the CTLA-4, PD1–PD-L1 pathway in other solid tumors have recently been used, as the PD-L1 pathway is used by cancer cells for immunosuppression of their environment and the promotion of tumor growth (Alsaab et al. 2017). However, although ACC tumors have some PD-L1 expression (Fay et al. 2015), clinical trials showed success in the minority of patients. Researchers have pointed out that responsiveness to checkpoint blockade immunotherapy requires CD8+ cells, which are downregulated in ACC because of T53 mutations and WNT-β-catenin amplifications, both of which impair CD8’s action (Cosentini et al. 2018). Additionally, PD-L1 expression, although present in ACC, is lower than that in other cancers, and the glucocorticoid secretion level of some ACC tumors has an immunosuppressive effect that limits targeted therapy (Landwehr et al. 2020).

More recent studies have focused on pembrolizumab as salvage therapy, which also targets PD-1 and overall seems to be better tolerated. A literature review of four case series and four prospective studies (115 patients total) noted that pembrolizumab was well tolerated and associated with prolonged OS ranging from 4.3 to 31 months (Brabo et al. 2020).

While there is no robust data to compare the clinical outcomes of ACC patients treated with immune checkpoint inhibitors based on cortisol production, the preclinical and translational data suggest that the cortisol effect could limit the benefit of immunotherapy (Landwehr et al. 2020, Greenstein et al. 2021). Thus, controlling cortisol excess in theory could enhance the response to immunotherapy. There is currently an ongoing trial phase 1b trial to investigate the efficacy of the combination of relacorilant (a selective glucocorticoid receptor inhibitor) with pembrolizumab in ACC (Clinical Trial Identifier: NCT04373265).

Future prospective studies are needed to determine the effectiveness of using immunotherapy in the adjuvant setting.

**Conclusions**

ACC is an aggressive cancer with a high risk of recurrence. The main factors predicting tumor recurrence are advanced disease, positive surgical margins, high Ki67 percentage scores, mitotic indices, hormonally active tumors, and certain genetic and cluster subtypes. Despite significant progress in developing adjuvant therapies for ACC, the field is still evolving, and studies sometimes present conflicting data. Much of the data on adjuvant therapy comes from retrospective studies of both adjuvant and salvage therapy in patients with ACC. Thus, strong data are lacking given the absence of formal prospective studies and randomized controlled trials. Future research should include more prospective studies, including those examining the use of genetic profiling, to validate the usefulness of the predictors of ACC recurrence. Results from future prospective clinical trials of adjuvant mitotane, chemotherapy, RT, and, especially, immunotherapy are also needed to better inform practicing physicians about the best approaches to reduce ACC recurrence via adjuvant therapy.

**Declaration of interest**

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

**Funding**

This work was supported in part by the NIH/NCI under award number P30CA016672.

**Author contribution statement**

R A: Writing and editing the manuscript. C Z: Writing and editing the manuscript. M H: PI reviewing and editing the manuscript.

**Acknowledgements**

Editorial assistance was provided by Laura L Russell, The University of Texas MD Anderson Cancer Center Editing Services, Research Medical Library.

https://doi.org/10.1530/EO-22-0050

© 2022 The authors. Published by Bioscientifica Ltd. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References


Ramsay O 1899 Malignant tumors of the suprarenal girdle. The Johns Hopkins Hospital 94 96.


Received in final form 20 June 2022
Accepted 26 July 2022
Accepted Manuscript published online 26 July 2022